Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Relay Therapeutics, Inc. - Common Stock (NQ:RLAY)

3.450 +0.110 (+3.29%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 12, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,771,771
Open 3.300
Bid (Size) 3.380 (16)
Ask (Size) 3.430 (16)
Prev. Close 3.340
Today's Range 3.260 - 3.525
52wk Range 1.775 - 10.72
Shares Outstanding 121,613,181
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Relay Therapeutics Appoints Claire Mazumdar, Ph.D., to Board of Directors
From Relay Therapeutics, Inc.
Via GlobeNewswire
Relay Therapeutics Announces Updated Data for RLY-2608 + Fulvestrant Further Demonstrating Clinically Meaningful Progression Free Survival at ASCO 2025
From Relay Therapeutics, Inc.
Via GlobeNewswire

Performance

YTD
-19.8%
-19.8%
1 Month
+21.9%
+21.9%
3 Month
+1.2%
+1.2%
6 Month
-27.8%
-27.8%
1 Year
-56.0%
-56.0%

More News

Read More
Relay Therapeutics to Participate in Two Upcoming Investor Conferences in June
From Relay Therapeutics, Inc.
Via GlobeNewswire
Earnings Scheduled For February 26, 2025
Via Benzinga
Why Relay Therapeutics (RLAY) Stock Is Down 17% Today
Via Benzinga
Relay Therapeutics Reports First Quarter 2025 Financial Results and Corporate Updates
From Relay Therapeutics, Inc.
Via GlobeNewswire
Relay Therapeutics to Announce First Quarter 2025 Financial Results and Corporate Highlights on May 5, 2025
From Relay Therapeutics, Inc.
Via GlobeNewswire
This Twin Disc Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday
Via Benzinga
Relay Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Updates
From Relay Therapeutics, Inc.
Via GlobeNewswire
Relay Therapeutics to Participate in Two Upcoming Investor Conferences
From Relay Therapeutics, Inc.
Via GlobeNewswire
Relay Therapeutics to Announce Fourth Quarter and Full Year 2024 Financial Results and Corporate Highlights on February 26, 2025
From Relay Therapeutics, Inc.
Via GlobeNewswire
Relay Therapeutics to Present at 43rd Annual J.P. Morgan Healthcare Conference
From Relay Therapeutics, Inc.
Via GlobeNewswire
Relay Therapeutics Announces Updated Interim Data for RLY-2608 + Fulvestrant Demonstrating Continued Maturation of Clinically Meaningful Progression Free Survival
From Relay Therapeutics, Inc.
Via GlobeNewswire
Relay Therapeutics to Present Updated Clinical Data on RLY-2608 in HR+/HER2- Breast Cancer at 2024 San Antonio Breast Cancer Symposium
From Relay Therapeutics, Inc.
Via GlobeNewswire
Relay Therapeutics and Elevar Therapeutics Announce Exclusive Global Licensing Agreement for Lirafugratinib in FGFR2-Driven Cholangiocarcinoma and Other Solid Tumors
From Relay Therapeutics, Inc.
Via GlobeNewswire
Relay Therapeutics to Participate in Upcoming Investor Conferences
From Relay Therapeutics, Inc.
Via GlobeNewswire
Relay Therapeutics Reports Third Quarter 2024 Financial Results and Corporate Highlights
From Relay Therapeutics, Inc.
Via GlobeNewswire
Relay Therapeutics to Announce Third Quarter 2024 Financial Results and Corporate Highlights on November 6, 2024
From Relay Therapeutics, Inc.
Via GlobeNewswire
AI-Focused Drug Discovery Stocks +6% Last Week Vs. -8% Previous Week
Via Talk Markets
Why Relay Therapeutics Plummeted by Nearly 14% Today
Via The Motley Fool
This Novartis Analyst Is No Longer Bullish; Here Are Top Downgrades For Wednesday
Via Benzinga
GameStop Reports Weak Sales, Joins Petco, Relay Therapeutics And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
Via Benzinga
Why Dave & Buster's Shares Are Trading Higher By Around 13%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Relay Therapeutics Announces Pricing of Public Offering of Common Stock
From Relay Therapeutics, Inc.
Via GlobeNewswire
Relay Therapeutics Faces Downgrade Over Efficacy Concerns in Competitive PI3K Inhibitor Market
Via Benzinga

Frequently Asked Questions

Is Relay Therapeutics, Inc. - Common Stock publicly traded?
Yes, Relay Therapeutics, Inc. - Common Stock is publicly traded.
What exchange does Relay Therapeutics, Inc. - Common Stock trade on?
Relay Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Relay Therapeutics, Inc. - Common Stock?
The ticker symbol for Relay Therapeutics, Inc. - Common Stock is RLAY on the Nasdaq Stock Market
What is the current price of Relay Therapeutics, Inc. - Common Stock?
The current price of Relay Therapeutics, Inc. - Common Stock is 3.450
When was Relay Therapeutics, Inc. - Common Stock last traded?
The last trade of Relay Therapeutics, Inc. - Common Stock was at 06/12/25 04:00 PM ET
What is the market capitalization of Relay Therapeutics, Inc. - Common Stock?
The market capitalization of Relay Therapeutics, Inc. - Common Stock is 419.57M
How many shares of Relay Therapeutics, Inc. - Common Stock are outstanding?
Relay Therapeutics, Inc. - Common Stock has 420M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.